Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04993859
Other study ID # 20-0680.cc
Secondary ID P30CA0469341K23D
Status Recruiting
Phase
First received
Last updated
Start date June 2, 2021
Est. completion date July 9, 2025

Study information

Verified date August 2023
Source University of Colorado, Denver
Contact Gemma Beltran
Phone (720) 777-4418
Email gemma.beltran@childrenscolorado.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.


Description:

The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition. The global hypothesis is that childhood cancer survivors with prior exposure to systemic vincristine (VCR) and/or doxorubicin (DOX) report an increased incidence of bladder dysfunction (BD) symptoms on the Dysfunctional Voiding Symptom Score (DVSS) survey. We expect to observe differences in non-invasive urodynamic (niUDS) testing between childhood cancer survivors with BD symptoms on the DVSS versus those without BD symptoms on DVSS. We also expect to observe statistically significant differences in the urinary levels of known urinary biomarkers of BD (NGF, ATP and BDNF) of patients with evidence of BD compared to those without BD on the DVSS. We also expect to observe rational differences in the urinary proteome of patients between those with and without BD.


Recruitment information / eligibility

Status Recruiting
Enrollment 152
Est. completion date July 9, 2025
Est. primary completion date July 9, 2024
Accepts healthy volunteers No
Gender All
Age group 5 Years to 10 Years
Eligibility Inclusion Criteria: - Children aged 5-10 years old - A history of cancer - Treatment with a chemotherapy regimen including VCR and/or DOX - Completion of chemotherapy at least one year prior to study enrollment and survey completion. Exclusion Criteria: - Patients with a: - Primary pelvic tumor - Pelvic irradiation - Pre-existing bladder/bowel dysfunction - Spinal defects - Neurologic disorder - Neuro-oncologic tumor or brain metastasis - Cyclophosphamide or ifosfamide therapy

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Non-invasive Urodynamic Test (niUDS)
A noninvasive urodynamics is a simple test used to evaluate urinary flow.
Urinary proteomic screen
Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
Other:
Dysfunctional Voiding Symptom Score Survey (DVSS)
The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.

Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado

Sponsors (4)

Lead Sponsor Collaborator
University of Colorado, Denver Children's Hospital Colorado, National Cancer Institute (NCI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of non-normal niUDS patterns between groups a. Patterns will be scored by blinded reviewers b. Will calculate an Inter-rater Kappa correlation co-efficient i. Utilize consensus review for discrepancies between reviewers and between the patient's 1st/2nd niUDS for the final assignment ii. Will calculate an intra-test reliability (compare correlation between 1st and 2nd patter) c. Chi-square test to compare proportions of non-normal vs. normal pattern type i. Group 1a vs. 2a ii. Group 1b vs. 2b d. Sample Size Calculation: Based on published data of niUDS patterns in children with normal bladder function, we expect 15% of those children in Group 2 to have non-normal niUDS patterns. We hypothesize that 40% of children in Group 1 to have non-normal niUDS patterns. 38 subjects in each gender sub-group provide 80% power to detect this 25% difference with an one-sided chi-square test with an alpha of 0.05. Immediately after niUDS done at the first visit
Primary Proportion of Elevated Post-Void Residual (PVR) between groups a. Will use an "average PVR" between the 1st/2nd niUDS for the analysis b. Chi-square test to compare proportions of elevated PVR i. Group 1a vs. 2a ii. Group 1b vs. 2b c. Sample Size Calculation: Based on published data of PVR in children with normal bladder function, we expect 1.5% of those children in Group 2 to have elevated PVR. We hypothesize that 25% of children in Group 1 to have an elevated PVR. 21 subjects in each gender sub-group provide 80% power to detect this 23.5% difference with an one-sided chi-square test with an alpha of 0.05. 13 months
Primary Compare Peak Flow Rates (Qmax) between groups a. Will use the average of the two Qmax between the 1st/2nd flow rate for the analysis b. Two group t-test for comparing continuous variables (Qmax) i. Group 1a vs. 2a ii. Group 1b vs. 2b c. Sample Size Calculation: 38 subjects in Group 1a and 2a provide 80% power to detect an effect size of 0.7 (mean difference divided by the common standard deviation) using a 2-sided two-group test with an alpha of 0.05. if the outcome is not normally distributed, transformation will be carried out so the distribution will be approximately normal. This power calculation also applies to the comparison between Group 1b vs 2b 13 momths
Primary Compare Average Flow Rates (Qavg) for age/gender a. Will use the average of the two Qavg between the 1st/2nd flow rate for the analysis b. Two group ttest for comparing continuous variables (Qavg) i. Group 1a vs. 2a ii. Group 1b vs. 2b c. See the power calculation in 3c. 13 months
Primary Compare Urinary Biomarker Levels between groups 1. Compare urinary biomarker levels between groups i. ATP, BDNF, NGF ii. Two-group t-test for comparing continuous variables
Group 1 vs. 2
Sub-analysis
Group 1a vs. 2a
Group 1b vs. 2b The sample size calculation in 1d can apply to each biomarker. Based on published data in other populations with BD, for NGF, ATP and BDNF, we hypothesize to detect a difference of these urinary biomarkers 2x higher in Group 2 (Elevated DVSS scores) vs. Group 1 (Normal DVSS scores).
A mixed effects model will be used to estimate and compare a biomarker expression between the two groups by incorporating the individual measurements on each subject into the model, where gender and group assignment will be the predictor. Interaction term between group and gender will be considered to study the effect modification by gender on a biomarker if possible.
13 months
See also
  Status Clinical Trial Phase
Withdrawn NCT00713921 - Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients Early Phase 1
Withdrawn NCT00472784 - Quantitative and Qualitative Changes in Neural Efferent Receptors
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Completed NCT02910596 - Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Phase 4
Terminated NCT00688948 - Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) Phase 2/Phase 3
Completed NCT05858840 - Urinary Artificial Sphincter in Children
Recruiting NCT05968352 - Restoration of Bladder Function in Spinal Cord Injury
Recruiting NCT05462561 - Vascularized Composite Bladder Allograft Transplantation N/A
Completed NCT05013541 - Effect of Bladder Filling on Rectal Contractions During Cystometry
Recruiting NCT04626167 - Concomitant Renal and Urinary Bladder Allograft Transplantation Early Phase 1
Completed NCT03570593 - Removal of Urinary Catheter After Radical Surgery N/A
Active, not recruiting NCT04490642 - Linguistic Validation of the Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ) for 5-12 Years Old in Korean
Completed NCT04057222 - Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis
Not yet recruiting NCT06439862 - Study of the Quality of Life in School Aged-children With Posterior Urethral Valves
Recruiting NCT04835766 - Urodynamic Changes Following Bladder Injury
Completed NCT05351138 - Comparison of Transcutaneous Electrical Nerve Stimulation and Manual Therapy in Children With Cerebral Palsy N/A
Completed NCT03987126 - Prebiotics for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction Phase 3
Completed NCT01460303 - Patient-operated Valved Catheter Versus Indwelling Transurethral Catheter N/A
Completed NCT00280592 - Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients Phase 3
Completed NCT05861011 - Bladder Neck Surgery in Children With Neurogenic Bladder